Verastem Oncology

272 articles with Verastem Oncology

• Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology

  2/14/2019

  Verastem, Inc. announced that the results of the Phase 2 DYNAMO™ study, which evaluated COPIKTRA™ capsules in patients with indolent non-Hodgkin lymphoma who were refractory to both rituximab and chemotherapy or radioimmunotherapy, was published online in the [peer-reviewed] Journal of Clinical Oncology.

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on February 1, 2019

  2/4/2019

  Verastem, Inc. announced the grant of options to purchase 46,000 shares of its common stock to six new employees.

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on January 7, 2019

  1/7/2019

  Verastem, Inc. today announced the grant of options to purchase 19,467 shares of its common stock to three new employees and 22,200 restricted stock units (RSUs) to one new employee.

• Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Verastem, Inc. today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco, CA.

• Verastem Oncology Added to the NASDAQ Biotechnology Index®

  12/20/2018

  Verastem, Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). Verastem Oncology’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018.

• Verastem Oncology Announces First Recipient of the Care Differently Award for Excellence in Patient Support and Education

  12/19/2018

  Dr. Koffman is also the founder and volunteer Medical Director of the nonprofit CLL Society

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on December 3, 2018

  12/5/2018

  Verastem, Inc. today announced the grant of options to purchase 83,978 shares of its common stock to four employees.

• Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting

  12/4/2018

  Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies

• Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

  12/3/2018

  Combination of Duvelisib and Romidepsin Resulting in a 59% Overall Response Rate in Relapsed or Refractory Peripheral T-Cell Lymphoma

• Verastem Oncology Reports Third Quarter 2018 Financial Results

  11/7/2018

  Quarter Highlighted by FDA Approval of COPIKTRA™ (duvelisib) Capsules

• Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma

  11/7/2018

  Verastem, Inc. today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma

• Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

  11/6/2018

  Verastem, Inc. today announced a poster presentation of preclinical data by Jonathan Pachter, Ph.D., the Company’s Chief Scientific Officer, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C.

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on November 1, 2018

  11/5/2018

  Verastem, Inc. today announced the grant of options to purchase 6,153 shares of its common stock to one new employee and 40,000 restricted stock units (RSUs) to another new employee.

• Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting

  11/1/2018

  Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that eight abstracts have been selected for presentation, including one oral presentation, at the upcoming American Society of Hematology

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.

• Verastem Oncology Announces Executive Leadership Appointments and Changes

  10/18/2018

  Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.’s Chief Financial Officer Gina Consylman to its Board of Directors

• Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes

  10/12/2018

  Verastem, Inc. today announced the pricing of an offering of 5.00% Convertible Senior Notes due 2048 (the Convertible Notes) through a registered direct offering.

• National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  10/9/2018

  Verastem, Inc. today announced that the National Comprehensive Cancer Network® (NCCN®) added COPIKTRA™ (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

• National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology

  10/8/2018

  Verastem, Inc. today announced that the National Comprehensive Cancer Network® (NCCN®) added COPIKTRA™ (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for follicular lymphoma (FL).

• Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on October 1, 2018

  10/5/2018

  Verastem, Inc. today announced the grant of stock options to six new employees to purchase an aggregate of 193,980 shares of Verastem Oncology's common stock and 50,000 restricted stock units (RSUs) to one new employee.